NO20091495L - Pyrazolopyrimidinderivat - Google Patents

Pyrazolopyrimidinderivat

Info

Publication number
NO20091495L
NO20091495L NO20091495A NO20091495A NO20091495L NO 20091495 L NO20091495 L NO 20091495L NO 20091495 A NO20091495 A NO 20091495A NO 20091495 A NO20091495 A NO 20091495A NO 20091495 L NO20091495 L NO 20091495L
Authority
NO
Norway
Prior art keywords
formula
compound represented
hsp90
compound
antitumor activity
Prior art date
Application number
NO20091495A
Other languages
English (en)
Norwegian (no)
Inventor
Satoru Ohsuki
Atsushi Tengeiji
Masahiro Ikeda
Yoshihiro Shibata
Chikahiro Nagata
Takashi Shimada
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of NO20091495L publication Critical patent/NO20091495L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20091495A 2006-09-19 2009-04-16 Pyrazolopyrimidinderivat NO20091495L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006253465 2006-09-19
PCT/JP2007/067933 WO2008035629A1 (en) 2006-09-19 2007-09-14 Pyrazolopyrimidine derivative

Publications (1)

Publication Number Publication Date
NO20091495L true NO20091495L (no) 2009-06-18

Family

ID=39200455

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091495A NO20091495L (no) 2006-09-19 2009-04-16 Pyrazolopyrimidinderivat

Country Status (25)

Country Link
US (1) US8158638B2 (da)
EP (1) EP2065388B1 (da)
JP (1) JP5252636B2 (da)
KR (2) KR20140127367A (da)
CN (1) CN101541811B (da)
AT (1) ATE523513T1 (da)
AU (1) AU2007298286B2 (da)
BR (1) BRPI0717176A2 (da)
CA (1) CA2663965C (da)
CO (1) CO6210702A2 (da)
CY (1) CY1112191T1 (da)
DK (1) DK2065388T3 (da)
ES (1) ES2373160T3 (da)
IL (1) IL197513A (da)
MX (1) MX2009002998A (da)
MY (1) MY145041A (da)
NO (1) NO20091495L (da)
NZ (1) NZ575564A (da)
PL (1) PL2065388T3 (da)
PT (1) PT2065388E (da)
RU (1) RU2420530C2 (da)
SI (1) SI2065388T1 (da)
TW (1) TWI388563B (da)
WO (1) WO2008035629A1 (da)
ZA (1) ZA200901921B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1008000A2 (pt) 2009-02-25 2016-02-23 Daiichi Sankyo Co Ltd composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto.
EP2414359A1 (en) * 2009-03-31 2012-02-08 ArQule, Inc. Peri-fused pyrazolo-pyrimidine compounds
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
EP2810945A1 (en) 2010-08-23 2014-12-10 Daiichi Sankyo Company, Limited Dihydrochloride salt of a tricyclic pyrazolopyrimidine derivative
TW201213334A (en) 2010-08-23 2012-04-01 Daiichi Sankyo Co Ltd Crystal forms of free form of tricyclic pyrazolopyrimidine derivative
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
CN114380738A (zh) * 2021-09-28 2022-04-22 都创(重庆)医药科技有限公司 一种3-溴-4-氯-2-甲基吡啶的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038446A1 (en) * 1995-05-31 1996-12-05 Eisai Co., Ltd. Fused polycyclic heterocycle derivatives
GB9615934D0 (en) 1996-07-30 1996-09-11 Netlon Ltd Integral tube
JP2001526639A (ja) * 1997-04-02 2001-12-18 アマーシャム・ファルマシア・バイオテック・ユーケイ・リミテッド 三環式塩基類似体
EP0973788A1 (en) * 1997-04-02 2000-01-26 Amersham Pharmacia Biotech UK Limited Tricyclic base analogues
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
NZ546055A (en) * 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
MXPA06002997A (es) * 2003-09-18 2007-02-08 Conforma Therapeutics Corp Novedosos compuestos heterociclicos como inhibidores- hsp90.
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs

Also Published As

Publication number Publication date
KR20090066274A (ko) 2009-06-23
MX2009002998A (es) 2009-04-02
IL197513A0 (en) 2009-12-24
CN101541811A (zh) 2009-09-23
PT2065388E (pt) 2011-11-10
MY145041A (en) 2011-12-15
KR20140127367A (ko) 2014-11-03
PL2065388T3 (pl) 2012-02-29
ES2373160T3 (es) 2012-02-01
HK1127476A1 (en) 2009-09-25
JPWO2008035629A1 (ja) 2010-01-28
NZ575564A (en) 2011-02-25
EP2065388B1 (en) 2011-09-07
US8158638B2 (en) 2012-04-17
CA2663965C (en) 2012-06-12
AU2007298286B2 (en) 2011-02-03
RU2420530C2 (ru) 2011-06-10
ATE523513T1 (de) 2011-09-15
SI2065388T1 (sl) 2012-03-30
AU2007298286A1 (en) 2008-03-27
EP2065388A1 (en) 2009-06-03
KR101485199B1 (ko) 2015-01-22
BRPI0717176A2 (pt) 2013-10-15
WO2008035629A1 (en) 2008-03-27
CN101541811B (zh) 2014-07-09
CA2663965A1 (en) 2008-03-27
EP2065388A4 (en) 2009-11-18
TW200823223A (en) 2008-06-01
DK2065388T3 (da) 2012-01-09
IL197513A (en) 2014-01-30
JP5252636B2 (ja) 2013-07-31
RU2009114731A (ru) 2010-10-27
TWI388563B (zh) 2013-03-11
CO6210702A2 (es) 2010-10-20
ZA200901921B (en) 2009-12-30
US20100113410A1 (en) 2010-05-06
CY1112191T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
CY1112191T1 (el) Παραγωγο πυραζολοπυριμιδινης
DK1853602T3 (da) Kemiske forbindelser
CY1108275T1 (el) Χημικες ενωσεις
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
TW200716606A (en) Chemical compounds
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
EA201170344A1 (ru) Азаиндольные ингибиторы iap
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
MXPA05010020A (es) Derivados de oxamida.
MX2011008677A (es) Derivados de pirazolopirimidina triciclicos.
ATE509956T1 (de) Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
MX2009005912A (es) Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos.
IL191670A0 (en) Compounds for the inhibition of apoptosis
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie
TNSN07283A1 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
MX2007013305A (es) Nuevas tiazolidinonas sin nitrogeno basico, su produccion y su uso como agentes farmaceuticos.
TH159358A (th) สารยับยั้งไพริดิลของการส่งสัญญาณเฮดจ์ฮ็อก
UA93197C2 (ru) Производные пиразолиламинопиридина, способ их получения, их применения и фармацевтическая композиция (варианты)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application